Previous studies of aracjiidonic acid metabolism in human colonic mucosa have concentrated on products of the cyclo-oxygenase (prostaglandin synthetase) pathway. The synthesis of prostanoids such as prostaglandin E2 (PGE2), PGF2I,, prostacyclin, its breakdown product 6-keto PGF1,, and thromboxane B2 (TXB2) is increased during relapse in inflammatory bowel disease. 1-5 These compounds may play a role in the inflammation -for example, by enhancing vasodilatation and oedema formation.6 7 They have little or no effect, however, in activating human leucocytes: indeed, prostacyclin (PGI2) in low concentrations has been shown to prevent polymorphonuclear leucocyte chemotaxis. 8 Prostaglandin synthesis alone is therefore unlikely
to lead to the accumulation of leucocytes during relapse in inflammatory bowel diseases. Indeed, specific potent inhibitors of prostaglandin synthesis such as indomethacin or flurbiprofen have not been shown to be of benefit in ulcerative colitis.911
The metabolism of arachidonic acid via lipoxygenase enzymes has been recently described in leucocytes and platelets.7 12T14he products formed include the leukotrienes and 5-hydroxyeicosatetraenoic acid (5-HE1t) from the 5-lipoxygenase pathway, and 12-and 15-HETE formed by the 12-and 15-lipoxygenase enzymes. In addition non-prostaglandin products of the cyclooxygenase pathway such as 11-HETE and 12-hydroxy-heptadecatrienoic acid (HHT) can be formed. In contrast with prostaglandins, some of these lipoxygenase products can stimulate locomotion, lysosomal enzyme release, and superoxide production by human leucocytes.7 12 1517 As the synthesis of lipoxygenase products by solid tissues such as skin, pericardium, pleura, and peritoneum have also been shown18 19 and because of the potential importance of such compounds in inflammatory bowel diseases, we have investigated whether human colonic mucosa also possesses the ability to metabolise radiolabelled arachidonic acid by lipoxygenase pathways.
Methods

PATIENTS
Human colon was obtained at operation from five patients undergoing resection of carcinomas in the rectum, sigmoid, or descending colon and from two patients undergoing colectomy for ulcerative colitis. The colonic mucosa of the patients with ulcerative colitis had the histological appearances of severe inflammation. The mucosa from the other patients (control tissue) was taken >5 cm away from the tumour, and was histologically normal. Both patients with ulcerative colitis were untreated at the time of operation, while none of the patients was receiving any drug known to affect arachidonic acid metabolism.
Mucosal tissue (which had been stripped from the resected human colon and stored at -70°C) was manually homogenised in 50 mM Tris (pH 8.0) using a 'Dual' ground glass homogeniser, to give a 50-85 mg/ml w/v final suspension. Aliquots (2 ml) were incubated for 20 minutes at 37°C with 840 ng (160 nCi) of 11-, 12 -, 15-HETE band (resolved using solvent system 'A') was scraped from the thin layer chromatography plate and eluted with methanol (20 ml). The eluant was dried under nitrogen and the residue redissolved in 50 ,u1 of solvent (see below) for injection into the high performance liquid chromatography (HPLC) column.
The dissolved residue was injected into a straightphase Zorbax Sil Column (Dupont 4.6x250 mm) previously equilibrated (3 ml/min) with solvent (n-hexane:isopropyl alcohol:acetic acid, 992:7:1, v/v/v) and standardised using authentic mono HETEs (11-, 12-, and 15-). Elution of metabolites was monitored by ultraviolet absorbance (280 and 254 nm). Fractions were collected every 30 seconds and radioactivity measured. Authentic 15-HETE was added to extracted samples as an internal standard.
DRUGS AND CHROMATOGRAPHIC STANDARDS
The arachidonic acid metabolites were characterised by co-chromatography with the following standards: (Fig. 1) . The predominant cyclo-oxygenase products formed, as characterised by their chromatographic mobility using solvent system 'B' (Fig. 2) were PGE2>PGF2,,>PGD2>TXB2>6-keto PGFl,.
The formation of these cyclo-oxygenase products was inhibited concentration-dependently by the cyclo-oxygenase inhibitor indomethacin (0.3-8 ,uM) and by the dual cyclo-oxygenase-lipoxygenase inhibitor,20 22 BW775C (1-38 ,uM). Concentrations of indomethacin (2.8 ,uM) and BW775C (19 uM) which were close to the IC50 values (concentration causing 50% reduction) for inhibition of these cyclo-oxygenase products were chosen for further studies, and the results are shown in Table 1 .
The predominant lipoxygenase products, characterised using solvent system 'A' (Fig. 3) , had a chromatographic mobility corresponding with 11-, 12-, or 15-HETE (which ran together). Whereas indomethacin (2.8 ,uM) failed to reduce significantly the formation of these products, BW775C (19 ,uM) inhibited their production by 75±9%, n=5 (p<0001; Table 1 ).
Smaller amounts of other products were also separated using solvent system 'A'. These were (a) product II, a band with a chromatographic mobility (Raa, 0.83) slightly greater than the 11-, 12-, 15-HETE band, whose production was inhibited by BW775C (19 ,M) but not by indomethacin (2.8 inflamed mucosa both to the products separated using solvent system 'A' and to the cyclo-oxygenase products separated using solvent system 'B' ( Table  2) .
HPLCOFTHE II-, I2-, I5-HETE BAND
The radioactivity co-chromatographing with the 11-, 12-, 15-HETE thin layer chromatography band was further resolved using HPLC techniques (Fig. 4) . from endogenous precursor corresponding to 12-HETE, although they did not quantify its production. The detection of 12-HETE by mucosal homogenates in both studies, as with TXB2, may reflect formation by entrapped platelets, which are known to convert efficiently arachidonic acid to this lipoxygenase product as well as to TXB2,12 22 but their formation by other cell types from the colonic mucosa cannot be excluded. The production of 15-HETE by human colonic mucosa is a novel finding. As patients with ulcerative colitis rarely come to operation while untreated, only a single HPLC experiment could be performed on the products formed by inflamed tissue. Thus any conclusions concerning the differences between inflamed and control mucosa are necessarily limited. The 15-HETE found in homogenates of the inflamed and uninflamed mucosa may reflect lipoxygenase activity derived from leucocytes which have infiltrated the mucosa. Although the major lipoxygenase product generated by intact rabbit neutrophils is 5-HETE,13 in brokencell preparations the predominant product formed is 15-HETE.14 Furthermore, 15-HETE is the major mono-HETE formed in intact human polymorphonuclear leucocytes incubated with arachidonic acid24 and in an enriched fraction of human eosinophils, 25 as well as in rabbit peritoneal tissue26 and human lung.27
The increased capacity of inflamed colonic mucosa to form prostaglandins and thromboxane has been shown previously. 5 We have now confirmed these observations, using the conversion of [14C]-AA as an index of cyclo-oxygenase activity, but in addition an increase in the formation of radiolabelled lipoxygenase products was also observed. Whether this increase is entirely due to the greater number of inflammatory cells in the inflamed mucosa, or to an increase in the capacity of other cells in the mucosa to metabolise arachidonic acid requires further investigation.
We 
